ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Eisai Co., Ltd.

  • 6,354.00 JPY
  • -93.00
  • -1.44%
  • Japan
    Apr 22, 2019
  • Ticker
    TKS(4523)
  • Prev. close
    6,447
  • Market cap (JPY)
    1,911.96B
  • Market cap (USD)
    17,083.33M
  • Shares
    296.56M

Business Summary

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue600,054M5,414.06M
Gross Profit386,599M3,488.14M
Operating income75,595M682.06M
Income before tax76,803M692.96M
Net income51,845M467.77M
EBITDA101,778M918.30M
Diluted EPS180.971.63
Dividends Per Share1501.35
Total Assets1,049.03B9,863.94M
Total liabilities434,934M4,089.64M
Total equity593,582M5,581.39M
Operating cash flow149,649M1,350.22M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 599,490M 548,465M 547,922M 539,097M 600,054M
Gross Profit 390,525M 340,580M 339,839M 331,091M 386,599M
Operating income 64,373M 27,778M 42,779M 51,205M 75,595M
Income before tax 62,298M 25,875M 50,473M 57,668M 76,803M
Net income 38,251M 43,254M 54,933M 39,359M 51,845M
EBITDA 104,302M 66,718M 76,843M 77,689M 101,778M
Diluted EPS 134.01 151.37 191.76 137.41 180.97
Dividends Per Share 150 150 150 150 150
Total Assets 973,823M 1,053.81B 973,987M 1,030.76B 1,049.03B
Total liabilities 444,418M 451,757M 397,159M 428,172M 434,934M
Total equity 526,321M 598,748M 573,660M 584,630M 593,582M
Operating cash flow 91,276M 76,022M 95,617M 75,851M 149,649M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 5,984.63M 4,992.55M 4,562.81M 4,978.38M 5,414.06M
Gross Profit 3,898.56M 3,100.22M 2,830.00M 3,057.51M 3,488.14M
Operating income 642.62M 252.85M 356.24M 472.86M 682.06M
Income before tax 621.91M 235.53M 420.31M 532.54M 692.96M
Net income 381.85M 393.73M 457.45M 363.46M 467.77M
EBITDA 1,041.23M 607.31M 639.90M 717.43M 918.30M
Diluted EPS 1.33 1.37 1.59 1.26 1.63
Dividends Per Share 1.49 1.36 1.24 1.38 1.35
Total Assets 9,455.96M 8,787.30M 8,665.75M 9,250.32M 9,863.94M
Total liabilities 4,315.36M 3,766.99M 3,533.60M 3,842.51M 4,089.64M
Total equity 5,110.65M 4,992.68M 5,103.96M 5,246.61M 5,581.39M
Operating cash flow 911.19M 692.01M 796.24M 700.45M 1,350.22M

Valuation Measures

Mar 2018
PER37.42
ROA4.98%
ROE8.80%
Operating margin12.59%
Profit margin8.64%

Key executives

  • Chief Executive Officer & Representative Director: Haruo Naito
  • Chief Financial Officer & Chief IR Officer: Ryohei Yanagi
  • Chief Information Officer: Hideki Hayashi
  • Chief Compliance Officer & Executive Officer: Junichi Asatani
  • Vice President: Yasunobu Kai

Shareholders

  • Wellington Management Co. LLP (8.6%)
  • Nomura Asset Management Co., Ltd. (5.0%)
  • Nippon Life Insurance Co. (4.1%)
  • Eisai Co., Ltd. (3.4%)
  • BlackRock Fund Advisors (2.8%)
  • Nikko Asset Management Co., Ltd. (2.7%)
  • Daiwa Asset Management Co. Ltd. (2.4%)
  • Resona Holdings, Inc. (2.4%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.4%)
  • The Vanguard Group, Inc. (2.2%)

Contact Details

  • Website:http://www.eisai.co.jp
  • Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
  • Phone: +81.3.3817.3700

Related Companies

  • Eisai LLC
  • Eisai Machinery China Co. Ltd.
  • Eisai Laboratorios S de RL de CV
  • Eisai GesmbH
  • Eisai Farmaceutica, Unipessoal Lda.
  • Eisai Clinical Research Singapore Pte Ltd.
  • Eisai Ltd. (Canada)
  • Eisai SA/NV
  • Eisai (Malaysia) Sdn. Bhd.
  • Eisai (Thailand) Marketing Co. Ltd.
  • Eisai AB
  • Eisai Pharma AG
  • Eisai (Singapore) Pte Ltd.
  • Eisai Co. Ltd. /Misato Factory/
  • Eisai Board Incentive Plan
  • Eisai Corporate Pension Fund
  • Eisai Pension Fund
  • Eisai China, Inc.
  • H3 Biomedicine, Inc.
  • Herusu Co., Ltd.
  • Gakuen Shoji Co., Ltd.
  • PT Eisai Indonesia
  • Eisai Taiwan, Inc.
  • Eisai (Hong Kong) Co. Ltd.
  • Eisai Australia Pty Ltd.
  • Eisai Pharmaceuticals India Pvt Ltd.
  • Eisai GmbH
  • Eisai SRL
  • Eisai London Research Laboratories Ltd.
  • Ea Pharma Co., Ltd.

Competitors

  • Ipsen SA
  • Nektar Therapeutics
  • Celgene Corporation
  • Binex Co., Ltd
  • Sienna Biopharmaceuticals, Inc.
  • Kiniksa Pharmaceuticals Ltd. Class A
  • ArQule, Inc.
  • Exelixis, Inc.
  • Blueprint Medicines Corp.
  • Calithera Biosciences, Inc.
  • Denali Therapeutics Inc.
  • Genfit SA
  • SillaJen, Inc.
  • Aquestive Therapeutics, Inc.
  • Aslan Pharmaceuticals Ltd.
  • Infinity Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • arGEN-X SE
  • Orexigen Therapeutics, Inc.
  • Probiodrug AG
  • Heron Therapeutics Inc
  • Onxeo SA
  • ProMIS Neurosciences Inc.
  • Aileron Therapeutics, Inc.
  • Onconova Therapeutics Inc.
  • Radius Health Inc
  • VIVUS, Inc.
  • ACADIA Pharmaceuticals Inc.
  • AVEO Pharmaceuticals, Inc.
  • Cytokinetics, Incorporated
Last Updated on 22 Apr, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 19th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media